Immunicom: A Single Immunotherapy Solution to Potentially Treat all Solid-Tumor Cancers Without Compromises

Top 10 BioTech Startups

One thing constant in this world is change. Every single day, there are changes in every aspect of daily existence with new technological breakthroughs and advancements in knowledge. One of the industries that face many changes is in biotechnology with constant research, tech improvements, and scientific discoveries.

In this field, all businesses, research institutions, and organizations that deal with the improvement of the quality of life of all organisms is taken in to account. In terms of the human health, this includes understanding of diseases so mankind can benefit from the studies and researches; and thereby, fight against these health pandemics. Today, early stage biotech funding is dominated by the “venture creation model”. In the venture creation model, the VC firm creates the company. They have an initial idea and put together a team of favoured executives, often from their pool of entrepreneurs-in-residence, to run it. The startup is typically incubated out of the VC’s offices. The VC invests a large amount of money upfront and takes a controlling ownership stake.

Just as VC-incubated tech companies made sense when tech companies were expensive to start, this model made sense when the cost to start a biotech company was high. Until recently, no one could get anything done before a VC wrote a $10M check, so this was the only way to get started. Because of this infrastructure, bio companies routinely clear major scientific hurdles during YC’s short program. Often therapeutics companies are able to show that their concept is effective in animal models. Diagnostic companies can show success with human samples. Synthetic biology companies successfully engineer cell lines.

We present to you 10 Most Promising BioTech Startups - 2020

    Top BioTech Startups

  • Founded in 2013, Amnio Technology is working dedicatedly to optimize the regenerative capability and clinical use of these amniotic tissues. Today, the company has emerged as a global leader in developing and distributing amniotic tissue allografts. Amnio Technologies’ PalinGen® Flow is an amniotic tissue allograft that it recovers during elective Cesarean delivery with maternal consent. It is comprised of amniotic fluid-derived elements including extracellular material and proteins, and micronized amnion membrane, yielding a fluid allograft for subcutaneous injection. This jump-starts the healing process

  • Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy has the potential to allow the body’s natural immune system to directly attack the cancer while enhancing the effects of other cancer treatments which may be used concurrently

  • Russell Health is a national distributor of safe and effective regenerative therapy products. The company’s Stem Cell Recruitment Therapy® is a breakthrough procedure that helps the body boost its ability to heal itself. Russell Health’s minimally invasive products can be used as an alternative to expensive and high-risk surgical interventions for patients. This is highly beneficial for elderly citizens as they can avoid operative care before and after surgery, along with its risks. Further, Stem Cell Recruitment Therapy® can substitute opioid drugs currently used by patients. The company has achieved profound clinical outcomes in multiple therapeutic areas, including cosmetics, wound care, pain management, podiatry, orthopedics, dentistry, and gynecology

  • Aegle Therapeutics

    Aegle Therapeutics

    Aegle Therapeutics is developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including dystrophic epidermolysis bullosa, a rare pediatric blistering disease. Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare genetic pediatric connective tissue disorder

  • Anima Biotech

    Anima Biotech

    Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against hard and undruggable targets in many diseases. Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture

  • Avectas


    Avectas is a cell engineering business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique delivery technology platform, Solupore®, to enable the ex-vivo manufacture of gene modified cell therapy products, with partners. Solupore® is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality

  • Concarlo Holdings

    Concarlo Holdings

    Concarlo Holdings, LLC (Concarlo) is an oncology company focused on diagnosing and treating cancer by targeting a unique cellular pathway. The firm’s approach is based on the role of p27Kip1 — a key “ON-OFF” switch that modulates the activities of critical proteins involved in many cancers: CDK4, CDK6, and CDK2. Concarlo is commercializing therapeutics to treat metastatic cancer alongside a diagnostic to identify patients who will respond to therapy

  • Jasper Therapeutics

    Jasper Therapeutics

    Jasper is a biotechnology company focused on developing and commercializing safer, more effective conditioning agents to allow for expanded use of curative therapy with stem cell transplantation and gene therapies. The firm’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic (blood and bone marrow) stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. Jasper plans to expand its pipeline to other novel therapies for immune modulation, graft engineering and cell and gene therapies

  • Kineta


    Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. The firm has leveraged their expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and virology. Kineta has established strategic partnerships with leading science-driven organizations to accelerate the development of our pipeline of novel immunotherapies. The firm also collaborates with a broad array of private, government and industry partners to advance our innovative research

  • Pace Diagnostics

    Pace Diagnostics

    Pace Diagnostics is an emerging biotechnology company focused on the research, development, licensing, manufacturing and marketing of cutting-edge diagnostics. Formed, based on the culmination of decades of basic and applied research, supported by grants and contracts from the US Federal Government, their vision is to create breakthrough point-of-care (POC) diagnostics to revolutionize improvements in healthcare for better living. Through their novel, high-throughput platform, and potent biomarkers, they are developing a comprehensive portfolio of POC diagnostics, with their lead developments in Tuberculosis and the early detection of lung cancer